These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12603253)

  • 1. Clinical findings in nondemented mutation carriers predisposed to Alzheimer's disease: a model of mild cognitive impairment.
    Almkvist O; Axelman K; Basun H; Jensen M; Viitanen M; Wahlund LO; Lannfelt L
    Acta Neurol Scand Suppl; 2003; 179():77-82. PubMed ID: 12603253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
    Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
    J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation.
    Wahlund LO; Basun H; Almkvist O; Julin P; Axelman K; Shigeta M; Jelic V; Nordberg A; Lannfelt L
    Dement Geriatr Cogn Disord; 1999; 10(6):526-33. PubMed ID: 10559570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychological function in nondemented carriers of presenilin-1 mutations.
    Ringman JM; Diaz-Olavarrieta C; Rodriguez Y; Chavez M; Fairbanks L; Paz F; Varpetian A; Maldonado HC; Macias-Islas MA; Murrell J; Ghetti B; Kawas C
    Neurology; 2005 Aug; 65(4):552-8. PubMed ID: 16116115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.
    Reiman EM; Quiroz YT; Fleisher AS; Chen K; Velez-Pardo C; Jimenez-Del-Rio M; Fagan AM; Shah AR; Alvarez S; Arbelaez A; Giraldo M; Acosta-Baena N; Sperling RA; Dickerson B; Stern CE; Tirado V; Munoz C; Reiman RA; Huentelman MJ; Alexander GE; Langbaum JB; Kosik KS; Tariot PN; Lopera F
    Lancet Neurol; 2012 Dec; 11(12):1048-56. PubMed ID: 23137948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosing the mild cognitive impairment stage of Alzheimer's disease].
    Maruyama M; Matsui T; Tanji H; Ootsuki M; Nemoto M; Tomita N; Okamura N; Matsushita S; Higuchi S; Kodama M; Arai H; Sasaki H
    Seishin Shinkeigaku Zasshi; 2004; 106(3):269-80. PubMed ID: 15164576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network.
    Lee S; Viqar F; Zimmerman ME; Narkhede A; Tosto G; Benzinger TL; Marcus DS; Fagan AM; Goate A; Fox NC; Cairns NJ; Holtzman DM; Buckles V; Ghetti B; McDade E; Martins RN; Saykin AJ; Masters CL; Ringman JM; Ryan NS; Förster S; Laske C; Schofield PR; Sperling RA; Salloway S; Correia S; Jack C; Weiner M; Bateman RJ; Morris JC; Mayeux R; Brickman AM;
    Ann Neurol; 2016 Jun; 79(6):929-39. PubMed ID: 27016429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimer's Disease.
    Almkvist O; Rodriguez-Vieitez E; Thordardottir S; Amberla K; Axelman K; Basun H; Kinhult-Ståhlbom A; Lilius L; Remes A; Wahlund LO; Viitanen M; Lannfelt L; Graff C
    J Int Neuropsychol Soc; 2017 Mar; 23(3):195-203. PubMed ID: 28079014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from preclinical to dinical stage of Alzheimer's disease as shown by decline of cognitive function in carriers of the Swedish APP-mutation.
    Almkvist O; Axelman K; Basun H; Wahlund LO; Lannfelt L
    J Neural Transm Suppl; 2002; (62):117-25. PubMed ID: 12456057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mild cognitive impairment--an early stage of Alzheimer's disease?
    Almkvist O; Basun H; Bäckman L; Herlitz A; Lannfelt L; Small B; Viitanen M; Wahlund LO; Winblad B
    J Neural Transm Suppl; 1998; 54():21-9. PubMed ID: 9850912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.
    Acosta-Baena N; Sepulveda-Falla D; Lopera-Gómez CM; Jaramillo-Elorza MC; Moreno S; Aguirre-Acevedo DC; Saldarriaga A; Lopera F
    Lancet Neurol; 2011 Mar; 10(3):213-20. PubMed ID: 21296022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations.
    Lee GJ; Lu PH; Medina LD; Rodriguez-Agudelo Y; Melchor S; Coppola G; Braskie MN; Hua X; Apostolova LG; Leow AD; Thompson PM; Ringman JM
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):154-62. PubMed ID: 23085935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life.
    Hausner L; Tschäpe JA; Schmitt HP; Hentschel F; Hartmann T; Frölich L
    Alzheimers Dement; 2014 Mar; 10(2):e27-39. PubMed ID: 23850332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biomarkers, mild cognitive impairment and early diagnosis of Alzheimer's disease].
    Arai H
    Nihon Ronen Igakkai Zasshi; 2003 Jan; 40(1):22-6. PubMed ID: 12649841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
    Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
    Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
    Andreasen N; Vanmechelen E; Vanderstichele H; Davidsson P; Blennow K
    Acta Neurol Scand Suppl; 2003; 179():47-51. PubMed ID: 12603251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year follow-up of a patient with early-onset Alzheimer's disease with presenilin-2 N141I mutation - case report and review of the literature.
    Nikisch G; Hertel A; Kiessling B; Wagner T; Krasz D; Hofmann E; Wiedemann G
    Eur J Med Res; 2008 Dec; 13(12):579-84. PubMed ID: 19073399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.
    Balasa M; Vidal-Piñeiro D; Lladó A; Antonell A; Bosch B; Castellanos F; Bargalló N; Bartres-Faz D; Molinuevo JL; Sánchez-Valle R
    J Alzheimers Dis; 2012; 30(3):605-16. PubMed ID: 22426017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.